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Netherlands; d IVI Madrid, Madrid, Spain; e Biometrics, Ferring Pharmaceuticals, Copenhagen, Denmark; and
f Reproductive Health, Ferring Pharmaceuticals, Copenhagen, DenmarkObjective: To compare the efﬁcacy and safety of follitropin delta, a new human recombinant FSH with individualized dosing based on
serum antim€ullerian hormone (AMH) and body weight, with conventional follitropin alfa dosing for ovarian stimulation in women un-
dergoing IVF.
Design: Randomized, multicenter, assessor-blinded, noninferiority trial (ESTHER-1).
Setting: Reproductive medicine clinics.
Patient(s): A total of 1,329 women (aged 18–40 years).
Intervention(s): Follitropin delta (AMH <15 pmol/L: 12 mg/d; AMHR15 pmol/L: 0.10–0.19 mg/kg/d; maximum 12 mg/d), or follitro-
pin alfa (150 IU/d for 5 days, potential subsequent dose adjustments; maximum 450 IU/d).
Main Outcomes Measure(s): Ongoing pregnancy and ongoing implantation rates; noninferiority margins 8.0%.
Result(s): Ongoing pregnancy (30.7% vs. 31.6%; difference0.9% [95% conﬁdence interval (CI)5.9% to 4.1%]), ongoing implantation
(35.2% vs. 35.8%;0.6% [95% CI6.1% to 4.8%]), and live birth (29.8% vs. 30.7%;0.9% [95% CI5.8% to 4.0%]) rates were similar for
individualized follitropin delta and conventional follitropin alfa. Individualized follitropin delta resulted in more women with target
response (8–14 oocytes) (43.3% vs. 38.4%), fewer poor responses (fewer than four oocytes in patients with AMH <15 pmol/L) (11.8% vs.
17.9%), fewer excessive responses (R15orR20oocytes inpatientswithAMHR15pmol/L) (27.9%vs. 35.1%and10.1%vs. 15.6%, respec-
tively), and fewermeasures taken to prevent ovarian hyperstimulation syndrome (2.3%vs. 4.5%), despite similar oocyte yield (10.0 5.6 vs.
10.4 6.5) and similar blastocyst numbers (3.3 2.8 vs. 3.5 3.2), and less gonadotropin use (90.0 25.3 vs. 103.7 33.6 mg).
Conclusion(s): Optimizing ovarian response in IVF by individualized dosing according to pretreatment patient characteristics results in
similar efﬁcacy and improved safety compared with conventional ovarian stimulation.Received September 15, 2016; revised October 7, 2016; accepted October 24, 2016; published online November 29, 2016.
A.N.A. has received fees and grant support from EMD Serono, Ferring Pharmaceuticals, Finox, MSD, and Roche Diagnostics. S.M.N. has received fees and
grant support from Beckman Coulter, Besins, EMD Serono, Ferring Pharmaceuticals, Finox, MSD, and Roche Diagnostics. B.C.J.M.F. has received fees
and grant support from Actavis/Watson/Uteron, COGI, Dutch Heart Foundation, Dutch Research Counsel, EMD Serono, Euroscreen, Ferring Pharma-
ceuticals, Finox, OvaScience, Pantharei Bioscience, PregLem/Gedeon Richter, Roche Diagnostics, Teva, and theWorld Health Organization. B.M.K. and
J.-C.A. are employees of Ferring Pharmaceuticals. J.-C.A. has patent applications on follitropin delta granted and pending. J.A.G.-V. has nothing to
disclose.
Supported by Ferring Pharmaceuticals. The study was designed by the sponsor in collaboration with the academic investigators. Data collection and study
sites were monitored by an independent clinical research organization. The data were collected by the sponsor and analyzed as per the prespeciﬁed
statistical analysis plan and validated by an independent statistician.
Presented in part at the 32nd Annual Meeting of the European Society of Human Reproduction and Embryology, July 3–6, 2016, Helsinki, Finland.
A.N.A. and S.M.N. should be considered similar in author order.
Reprint requests: Joan-Carles Arce, M.D., Ph.D., Ferring Pharmaceuticals A/S, Reproductive Health, Global Clinical & Non-Clinical R&D, Kay Fiskers Plads 11,
Copenhagen DK-2300, Denmark (E-mail: jca@ferring.com).
Fertility and Sterility® Vol. 107, No. 2, February 2017 0015-0282
Copyright ©2016 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.fertnstert.2016.10.033
VOL. 107 NO. 2 / FEBRUARY 2017 387
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONClinical Trial Registration Number: NCT01956110. (Fertil Steril 2017;107:387–96. Copyright 2016 The Authors. Published by
Elsevier Inc. on behalf of the American Society for Reproductive Medicine. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/.)
Key Words: Antim€ullerian hormone, follitropin delta, OHSS, ovarian response, pregnancy
Discuss: You can discuss this article with its authors and with other ASRM members at https://www.fertstertdialog.com/users/
16110-fertility-and-sterility/posts/12852-23086T he ovarian response to stimulation with exogenousgonadotropins during IVF is a critical determinantof live birth rates and adverse outcomes (1, 2).
Healthcare providers and national guidelines recognize the
need for individualization of the starting dose of
gonadotropin by using predictive factors related to patient
characteristics and diagnostic markers of ovarian reserve
to attain an optimal oocyte yield while minimizing the risk
of an excessive response and ovarian hyperstimulation
syndrome (OHSS) (3, 4). In practice, clinicians are requried
to individualize treatment according to their own
experience, using subjective preferences for predicitive
parameters, because there is not a standard position
regarding which factors to take into account or the weight
of each factor when determining the dose. The
considerable individual heterogeneity in ovarian response
to the same dose of gonadotropin, the limited performance
of baseline patient characteristics including age, FSH, and
antral follicle count (AFC) in predicting ovarian response,
and their inconsistent clinical interpretation, as well as the
lack of validated dosing algorithms, have limited the
generalizability of efﬁcacious and safe ovarian stimulation
(3–6). Antim€ullerian hormone (AMH), a dimeric
glycoprotein produced by granulosa cells of preantral and
early antral follicles, can now be measured in serum by
robust automated assays at any time of the menstrual
cycle and exhibits superior prediction of ovarian response
to controlled ovarian stimulation over established
alternatives (7, 8).
Follitropin delta is a recombinant FSH (rFSH), uniquely
expressed in a human fetal retinal cell line, which owing
to differences in glycosylation proﬁle has a lower clearance
and induces a higher ovarian response in humans than exist-
ing rFSH preparations when administered at equal doses of
biological activity (IU) (9). The lack of comparability with
existing rFSH preparations combined with the strong clin-
ical need for improved predictability of response merited a
novel biomarker-driven dosing strategy to tailor the ovarian
stimulation according to each patient's proﬁle (10). Pharma-
cokinetic and pharmacodynamic simulation facilitated
development of an individualized dosing algorithm for folli-
tropin delta incorporating body weight, which inﬂuences
drug exposure, and pretreatment AMH levels, which predict
ovarian response (11). The dosing algorithm is speciﬁc for
follitropin delta, owing to the unique pharmacokinetic/
pharmacodynamic proﬁle of the compound (9), and is de-
signed to maintain ongoing pregnancy rates and reduce
the risk of extreme ovarian responses, both hypo- and hy-
perresponse, and OHSS as compared with current therapeu-
tic dosing strategies. A biomarker-driven strategy also
implied that the selected starting dose could be maintained388daily throughout stimulation without any obvious need for
adjustments. The Evidence-based Stimulation Trial with
Human rFSH in Europe and Rest of World (ESTHER-1) trial
compared the treatment strategy of individualized
follitropin delta dosing with that of conventional
follitropin alfa dosing for IVF, with the aim to maintain
efﬁcacy (noninferiority) and improve safety. The trial was
the ﬁrst prospective study to test an algorithm
incorporating robust pretreatment patient characteristics.
MATERIALS AND METHODS
Study Design
This was a randomized, controlled, assessor-blinded, interna-
tional, multicenter, noninferiority trial of individualized folli-
tropin delta vs. conventional follitropin alfa dosing. The trial
was conducted at 37 investigational sites in 11 countries
(Belgium, Brazil, Canada, Czech Republic, Denmark, France,
Italy, Poland, Russia, Spain, and United Kingdom). The trial
protocol (number 000004) was approved by the local regulato-
ry authorities and the independent ethics committees covering
all participating centers. The trial was performed in accordance
with the principles of the Declaration of Helsinki, the Interna-
tional Conference on Harmonization Guidelines for Good Clin-
ical Practice, and local regulatory requirements. All
participants provided written, informed consent.Study Participants
Women aged 18–40 years undergoing their ﬁrst IVF/intracy-
toplasmic sperm injection (ICSI) cycle and diagnosed with un-
explained infertility, tubal infertility, endometriosis stage I/II,
or with partners diagnosed with male factor infertility, were
eligible for the trial. Additional main inclusion criteria were
body mass index 17.5–32.0 kg/m2, regular menstrual cycles
of 24–35 days, presence of both ovaries, and early follicular
phase FSH serum concentration 1–15 IU/L. The main exclu-
sion criteria were endometriosis stage III–IV, history of recur-
rent miscarriage, and use of hormonal preparations (except
for thyroid medication) during the last menstrual cycle before
randomization. All inclusion/exclusion criteria are listed in
Supplemental Table 1 (available online).Study Randomization and Masking
Women were randomly assigned in a 1:1 ratio via a central
computer-generated randomization sequence, prepared by
an independent statistician. Randomization was stratiﬁed
by age (<35, 35–37, and 38–40 years) and performed in
blocks of four within trial sites. All investigators, embryolo-
gists, and central laboratory personnel were blinded to treat-
ment allocation.VOL. 107 NO. 2 / FEBRUARY 2017
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Women randomized to follitropin delta (FE 999049, Ferring
Pharmaceuticals) were given a ﬁxed daily SC dose, deter-
mined by their serum AMH level at screening by a central lab-
oratory using the automated Elecsys AMH immunoassay (12)
(Roche Diagnostics International) and body weight at
randomization (AMH <15 pmol/L: 12 mg; AMH R15 pmol/
L: 0.10–0.19 mg/kg; the maximum daily dose was 12 mg).
The follitropin delta dosing algorithm (detailed in
Supplemental Table 2) was programmed in the electronic
case report form, which calculated the correct dose (all pa-
tients had their AMH levels determined centrally at screening,
with results uploaded to the electronic case report form,
though only used for patients randomized to follitropin delta).
The deﬁned target for the follitropin delta dosing regimen was
11 oocytes with a range of 8–14 oocytes.
Women randomized to follitropin alfa (Gonal-f, EMD Se-
rono) were administered a daily SC standard dose of 150 IU
(11 mg) for the ﬁrst 5 days, in line with labeling and interna-
tional recommendations (13, 14); thereafter the dose could be
adjusted up or down according to follicular response, with
450 IU as the maximum daily dose allowed. Investigators
evaluated the need for dose adjustments in a treatment-
blinded manner on the basis of follicular development, and
requests for dose increases or decreases were implemented
as applicable by an unblinded study nurse.
Gonadotropin therapy with either study drug was initi-
ated on day 2–3 of the menstrual cycle. For both treatments,
on stimulation day 6, a GnRH antagonist (cetrorelix acetate,
Cetrotide, EMD Serono) 0.25 mg/d was initiated and
continued throughout the stimulation period. Triggering of
ﬁnal follicular maturation was performed as soon as three
or more follicles were R17 mm in diameter. For women
with <25 folliclesR12 mm, 250 mg recombinant hCG (cho-
riogonadotropin alfa, Ovitrelle, EMD Serono) was adminis-
tered. For women with 25–35 follicles R12 mm, 0.2 mg
GnRH agonist (triptorelin acetate, Gonapeptyl, Ferring Phar-
maceuticals) could be administered or the cycle canceled. For
women with >35 folliclesR12 mm, the cycle was canceled.
In the case of poor follicular development, deﬁned as the
investigator judging that three or more follicles with a diam-
eterR17 mm could not be reached by day 20, the cycle was
canceled.
Oocyte retrieval took place 36  2 hours after triggering
of ﬁnal follicular maturation. Oocytes could be inseminated
by IVF or ICSI, using ejaculated sperm by either partner or
donor. For women receiving GnRH agonist, all blastocysts
were cryopreserved. For women who received hCG, a single
blastocyst was transferred on day 5 for all women aged
%37 years and for women agedR38 years with a blastocyst
grade 3BB or higher available; otherwise two blastocysts were
transferred. Surplus blastocysts were cryopreserved for use
after trial completion. Vaginal P tablets (Lutinus/Endometrin,
Ferring Pharmaceuticals) 100 mg three times daily were pro-
vided for luteal phase support from the day after oocyte
retrieval for 13–15 days and then discontinued on conﬁrma-
tion of pregnancy by serum hCG. Ultrasound was performed
at 5–6 weeks and 10–11 weeks after blastocyst transfer toVOL. 107 NO. 2 / FEBRUARY 2017conﬁrm clinical and ongoing pregnancy, respectively. All
pregnancies were followed until 4 weeks after live birth.
Adverse events were recorded from signed informed consent
until the end-of-trial visit.Study Outcomes
The co-primary endpoints were ongoing pregnancy rate,
deﬁned by at least one intrauterine viable fetus 10–11 weeks
after transfer, and ongoing implantation rate, deﬁned as
number of intrauterine viable fetuses 10–11 weeks after
transfer divided by number of blastocysts transferred.
Prespeciﬁed secondary endpoints included pregnancy
outcomes and speciﬁcally live birth rates (deﬁned as the birth
of at least one live-born neonate), targeted ovarian response
(8–14 oocytes) and extreme ovarian response (<4, R15, or
R20 oocytes), embryology, safety, and adverse events. The
safety endpoints included the proportion of women with early
and late OHSS (including OHSS of moderate/severe grade,
classiﬁed using Golan's system [15]) and/or preventive inter-
ventions for early OHSS (i.e., cycle cancellation due to exces-
sive ovarian response, triggering with GnRH agonist, or use of
dopamine agonist in women withR20 follicles ofR12 mm).Statistical Analysis
The primary objective of this trial was to demonstrate nonin-
feriority of an individualized dosing regimen of follitropin
delta compared with conventional follitropin alfa dosing on
the co-primary endpoints ongoing pregnancy rate and
ongoing implantation rate. The noninferiority limit for the
risk difference between the two treatments was prespeciﬁed
at8.0% for both co-primary endpoints, as agreed with regu-
latory authorities, and therefore no adjustment for multiplicity
was required. On the basis of the results in the present trial, the
predeﬁned noninferiority margin of 8.0% would allow a
maximum difference in point estimates between the two treat-
ments of 2.7%, and is therefore tight, taking into account
variation among clinics. For each co-primary endpoint, a
two-sided 95% conﬁdence interval (CI) was established using
the Mantel-Haenszel method to combine results across age
strata. If the lower limit of the 95% CI was above 8.0%
(e.g., if it was 7.9%) for both co-primary endpoints for both
the modiﬁed intention-to-treat (mITT) and the per-protocol
populations, then noninferiority was established. The mITT
population excluded threewomen randomized but not exposed
to study drug, whereas the per-protocol population excluded
women with major deviations from the protocol impacting
the co-primary endpoints.
As planned sensitivity analyses, the homogeneity of risk
differences across sites were tested (16), and the treatment
comparison was adjusted for factors potentially impacting
the co-primary endpoints: insemination method, primary
reason for infertility, primary infertility, and smoking status.
Assuming that both primary endpoints, ongoing preg-
nancy rate and ongoing implantation rate, would equate to
25%–30%, and that <8% of the women would have a major
protocol deviation, a total sample size of 1,150 women would
have at least 80% power for demonstration of noninferiority.389
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manner when the co-primary endpoints were available for
approximately 70%–80% of the planned number of partici-
pants. On the basis of this blinded review, the sample size
was increased to 1,300.RESULTS
Baseline Characteristics
The trial was conducted between October 8, 2013 andMay 11,
2015, with live birth follow-up completed on January 11,
2016. A total of 1,329 eligible women were randomized, of
whom 1,326 were exposed to study drug: 665 to individual-
ized follitropin delta and 661 to conventional follitropin
alfa. Three women did not receive study drug. The trial and
participant ﬂow is shown in Supplemental Figure 1. Demo-
graphics and baseline characteristics were comparable be-
tween the two treatment groups (Table 1). A total of 1,122
women underwent blastocyst transfer, with 539 (95.9%) of
the individualized follitropin delta group and 536 (95.7%)
of the conventional follitropin alfa group having a single
blastocyst transfer.TABLE 1
Demographic and baseline characteristics.
Characteristic Individualized follitro
Age (y)
All women 33.4 
<35 394 (59
35–37 161 (24
38–40 110 (16
Race (%)
American Indian or Alaska Native 0
Asian 3.
Black or African American 1.
Native Hawaiian or other Paciﬁc Islander 0.
White 94
Body weight (kg) 64.7 
Body mass index (kg/m2) 23.7 
Infertility history
Duration of infertility (mo) 35.3 
Primary infertility (%) 70
Primary reason for infertility (%)
Unexplained 42
Tubal 13
Male factor 40
Endometriosis I/II 3.
Other 0.
Endometrial thickness (mm) 4.1 
Ovarian volume (mL) 6.2 
AFC, 2–10 mm (n) 14.7 
Endocrine proﬁle
AMH (pmol/L) 16.3 (9.0
FSH (IU/L) 7.5 (6.2
LH (IU/L) 4.5 (3.5
E2 (pmol/L) 158 (12
P (nmol/L) 1.7 (0.8
Inhibin A (pg/mL) 5.0 (5.0
Inhibin B (pg/mL) 94 (68
TSH (mIU/mL) 1.5 (1.0
Prolactin (mg/mL) 10.3 (7.4
Note: Values are mean  SD, median (interquartile range), or number (percentage), unless stated o
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390Co-primary and Live Birth Endpoints
Outcome data for the randomized and exposed women
(mITT population) are displayed in Table 2. The ongoing
pregnancy rate was 30.7% in the individualized follitropin
delta group and 31.6% in the conventional follitropin alfa
group, with a 95% CI for the difference of 5.9% to 4.1%.
The ongoing implantation rate was 35.2% in the individu-
alized follitropin delta group and 35.8% in the conven-
tional follitropin alfa group, with a 95% CI for the
difference of 6.1% to 4.8%. The lower bound of the
95% CI for both co-primary endpoints was above the pre-
speciﬁed noninferiority limit of 8.0%, and noninferiority
of individualized follitropin delta to conventional follitro-
pin alfa on ongoing pregnancy rate and ongoing implanta-
tion rate was demonstrated.
There was no difference in the other pregnancy end-
points, including the number of live births and the number
of neonates alive at 4 weeks, between individualized follitro-
pin delta and conventional follitropin alfa (Table 2). Similar
noninferiority conclusions were obtained with the per-
protocol analysis and sensitivity analyses, with no evidence
of site heterogeneity.pin delta (n[ 665) Conventional follitropin alfa (n[ 661)
3.9 33.2  3.9
.2) 392 (59.3)
.2) 167 (25.3)
.5) 102 (15.4)
0.2
8 4.4
1 1.8
5 0
.7 93.6
10.7 63.4  10.4
3.4 23.3  3.3
24.4 34.9  21.7
.7 71.3
.3 41.3
.8 14.5
.3 39.3
3 4.4
3 0.5
1.8 4.1  1.7
3.2 6.0  3.3
6.9 14.4  6.8
–24.8) 16.0 (9.1–25.5)
–9.2) 7.7 (6.5–9.4)
–5.8) 4.4 (3.6–5.8)
8–199) 162 (130–201)
–2.4) 1.7 (0.8–2.3)
–5.0) 5.0 (5.0–5.0)
–125) 97 (72–121)
–2.0) 1.5 (1.1–2.0)
–13.9) 9.8 (7.5–13.6)
therwise.
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TABLE 2
Primary and pregnancy outcomes.
Outcome per started cycle
Individualized follitropin delta
(n[ 665)
Conventional follitropin alfa
(n[ 661) Difference (95% CI)a
Primary endpoints
Ongoing pregnancyb 204 (30.7) 209 (31.6) 0.9% (5.9% to 4.1%)
Ongoing implantationc 206/585 (35.2) 209/584 (35.8) 0.6% (6.1% to 4.8%)
Secondary pregnancy endpoints
Women with live birthd 198 (29.8) 203 (30.7) 0.9% (5.8% to 4.0%)
Women with live neonate(s)
at 4 wk after birthe
198 (29.8) 201 (30.4) 0.6% (5.5% to 4.3%)
Birth weight (g)f 3,186  601 3,168  624 22.8 (97.2 to 142.8)
Gestational age (d)f 272.3  15.6 272.3  16.9 0.1 (3.1 to 3.3)
Positive hCGg 257 (38.6) 266 (40.2) 1.5% (6.8% to 3.7%)
Clinical pregnancyh 232 (34.9) 241 (36.5) 1.5% (6.6% to 3.6%)
Vital pregnancyi 211 (31.7) 221 (33.4) 1.6% (6.7% to 3.4%)
Implantationj 233/585 (39.8) 241/584 (41.3) 1.4% (7.0% to 4.2%)
Multiple pregnancy rate 4 (2.0) 8 (3.8) 2.0% (5.0% to 1.1%)
Note: Values are mean  SD or number (percentage), unless stated otherwise.
a The noninferiority limit for the risk difference between the two treatments was prespeciﬁed at 8.0% for both co-primary endpoints. For each binary endpoint, a two-sided 95% conﬁdence
interval was established using the Mantel-Haenszel method to combine results across age-strata. For birth weight and gestational age the two-sided 95% conﬁdence interval was based on a linear
model including age-strata as factor.
b At least one intrauterine viable fetus 10–11 weeks after transfer.
c Number of intrauterine viable fetuses 10–11 weeks after transfer divided by number of blastocysts transferred.
d The birth of at least one live neonate.
e At least one live neonate 4 weeks after birth.
f All live-born neonates.
g Positive according to the local laboratory's reference ranges.
h At least one gestational sac 5–6 weeks after transfer.
i At least one intrauterine gestational sac with fetal heart beat 5–6 weeks after transfer.
j Number of gestational sacs 5–6 weeks after transfer divided by number of blastocysts transferred.
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Table 3 shows ovarian response, embryology, and safety data
regarding OHSS and preventive measures. There were no sig-
niﬁcant differences between treatment groups in terms of
number of oocytes retrieved. Figure 1A shows that the num-
ber of oocytes retrieved increased markedly with increasing
AMH values with conventional stimulation, whereas the
number of oocytes obtained was more homogeneously
distributed with the individualized follitropin delta dosing,
with no difference in the number of good-quality blastocysts
between the two treatments. In the individualized follitropin
delta group, fewer women had an extreme ovarian response
(Fig. 1B) despite dose adjustments in 36.8% of the women
in the conventional follitropin alfa group, in contrast to
none in the individualized follitropin delta group.
Antim€ullerian hormone stratiﬁcation demonstrated a
reduction in both poor and excessive responses (Table 3).
Among potential hypo-responders (i.e., women with AMH
<15 pmol/L), individualized follitropin delta was associated
with more oocytes (8.0 vs. 7.0, P¼ .004) as well as a lower
(P¼ .039) incidence of women with poor response (fewer
than four oocytes) compared with conventional follitropin
alfa. Among potential hyper-responders (i.e., women with
AMHR15 pmol/L), individualized follitropin delta was asso-
ciated with fewer oocytes retrieved (11.6 vs. 13.3, P¼ .002) as
well as a lower incidence of patients with R15 or R20 oo-
cytes retrieved (P¼ .038 and P¼ .030, respectively) compared
with follitropin alfa. The total amount of gonadotropin used
was lower (P< .001) with individualized follitropin delta
despite the similar duration of stimulation. More women
reached the target response of 8–14 oocytes with individual-VOL. 107 NO. 2 / FEBRUARY 2017ized follitropin delta (43.3% vs. 38.4%, P¼ .019, representing
a relative increase of 13%).
In the individualized follitropin delta group, fewer women
(P¼ .005) required OHSS preventive measures
(Table 3). Figure 1C shows that the risk of requiring OHSS pre-
ventive interventions or experiencing OHSS increased with
increasing AMH and differed between treatments. In the group
of patients with polycystic ovaries, the incidence of early mod-
erate/severe OHSS and/or preventive interventions for early
OHSS was 7.7% with individualized follitropin delta and
26.7% with conventional follitropin alfa (P¼ .001). Women
who received OHSS preventive measures exhibited an ovarian
response in excess of thosewho developed OHSS and presented
with a clinically relevant manifestation of symptoms of hyper-
response (Supplemental Table 3). In the individualized follitro-
pin delta group, two women were hospitalized because of
OHSS, with a mean duration of hospitalization of 4.0 days,
compared with six women with a mean duration of 8.7 days
in the conventional follitropin alfa group (Table 3).
Apart from OHSS and OHSS preventive measures, there
was no difference in other adverse events between the two
treatment groups. The most common adverse events observed
with individualized follitropin delta and conventional folli-
tropin alfa were headache (14.6% and 13.3%, respectively),
procedural pain (7.4% and 7.9%), pelvic pain (6.9% and
6.2%), pelvic discomfort (5.7% and 3.8%), and vomiting in
pregnancy (4.5% and 4.5%).DISCUSSION
Comparing the two treatment strategies of individualized dosing
of follitropin delta, based on pretreatment AMH concentrations391
TABLE 3
Ovarian response, embryology, and safety secondary endpoints.
Outcome variable
Individualized
follitropin
delta (n[ 665)
Conventional
follitropin
alfa (n[ 661) P value
Ovarian response endpoints
Duration of stimulation (d) 8.9  1.9 8.6  1.7 .062a
Total dose (mg) 90.0  25.3 103.7  33.6 < .001a
Women with investigator-requested gonadotropin dose adjustmentsb 221 (33.2) 243 (36.8) .178c
Women with dose adjustments implemented 0 (0.0) 243 (36.8) < .001c
Poor response leading to cycle cancellationd 25 (3.8) 18 (2.7) .302e
Excessive response leading to triggering with GnRH agonistf 10 (1.5) 23 (3.5) .019e
Oocytes retrievedg (n) 10.0  5.6 10.4  6.5 .692a
Target ovarian responseg (8–14 oocytes retrieved) 275 (43.3) 247 (38.4) .019h
Extreme ovarian responseg
<4 orR15 oocytes 169 (26.6) 201 (31.3) .001h
<4 orR20 oocytes 92 (14.5) 118 (18.4) .002h
Ovarian response stratiﬁed by AMHg
Women with AMH <15 pmol/L (at risk of hypo-response) (n) 280 290
Oocytes retrieved (n) 8.0  4.3 7.0  3.9 .004i
Poor responders (<4 oocytes) 33 (11.8) 52 (17.9) .039c
Women with AMHR15 pmol/L (at risk of hyperresponse) (n) 355 353
Oocytes retrieved (n) 11.6  5.9 13.3  6.9 .002i
Excessive responders (R15 oocytes) 99 (27.9) 124 (35.1) .038c
Excessive responders (R20 oocytes) 36 (10.1) 55 (15.6) .030c
Fertilized oocytesj (n) 5.5  3.7 5.9  4.4 .498a
Fertilization ratej (%) 56.0  24.5 57.0  23.8 .530a
Embryos, day 3j
Total (n) 5.4  3.7 5.7  4.3 .590a
Good-qualityk (n) 4.2  3.3 4.5  3.7 .414a
Blastocysts, day 5j
Total (n) 3.3  2.8 3.5  3.2 .344a
Good-qualityl (n) 2.0  2.2 2.1  2.4 .580a
Cryopreserved (n) 1.9  2.4 2.2  2.6 .262a
Women with blastocysts cryopreserved 402 (60.5) 402 (60.8) .892c
Safety outcomes
Preventive interventions 15 (2.3) 30 (4.5) .005m
Early OHSSn
Any grade 17 (2.6) 20 (3.0) .291m
Moderate/severe 9 (1.4) 9 (1.4) .644m
Any grade and/or preventive intervention 31 (4.7) 41 (6.2) .046m
Moderate/severe and/or preventive intervention 24 (3.6) 34 (5.1) .019m
All OHSS
Any grade 23 (3.5) 32 (4.8) .238m
Moderate/severe 14 (2.1) 19 (2.9) .514m
Any grade and/or preventive intervention 37 (5.6) 53 (8.0) .037m
Moderate/severe and/or preventive intervention 29 (4.4) 44 (6.7) .013m
Hospitalization due to OHSS 2 (0.30) 6 (0.90) .108o
Mean duration of hospitalizationp (d) 4.0 8.7 .276i
Total duration of hospitalizationp (d) 8 52 N/Aq
Note: Values are mean  SD or number (percentage), unless stated otherwise. Data are for all women unless otherwise stated.
a Van Elteren test stratiﬁed by age group.
b Investigators were blinded to the trial medication and could request dose adjustment for both treatment groups based on transvaginal ultrasound assessment of follicular response. The follitropin
delta dose was, however, ﬁxed throughout stimulation, and no dose adjustments were implemented, whereas the follitropin alfa dose could be adjusted down or up to a maximum of 450 IU.
c c2 test.
d Deﬁned as the investigator judging that three or more follicles with a diameterR17 mm could not be reached by stimulation day 20.
e Likelihood ratio test based on logistic regression model including age-strata as factor.
f For women with 25-35 folliclesR12 mm, 0.2 mg GnRH agonist (triptorelin acetate, Gonapeptyl, Ferring Pharmaceuticals) was administered.
g For women who received triggering of ﬁnal follicular maturation.
h Based on likelihood ratio test comparing nested logistic regression models including AMH and log(AMH) to second order as covariate.
i Wilcoxon's test.
j For women with oocytes retrieved.
k An embryo with six or more blastomers and fragmentation%20%.
l A blastocyst of grade 3BB or higher.
m Based on likelihood ratio test comparing nested logistic regression models including log(AMH) as covariate.
n Onset%9 days after triggering of ﬁnal follicular maturation.
o Fisher's exact test.
p For women hospitalized due to OHSS.
q The total duration of hospitalization cannot be compared between groups using a statistical test because it is the sum within treatment group.
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FIGURE 1
Ovarian response relative to AMH. (A) Number of oocytes retrieved (two upper curves) and number of good-quality blastocysts available for transfer
(two lower curves) by serum AMH levels at screening for the two treatment groups; circles (conventional follitropin alfa) and squares (individualized
follitropin delta) illustrate the observed number1 SE; trend lines are penalized B-splines of degree 1. (B) Proportion of women achieving the target
number of oocytes retrieved (8–14) by serum AMH levels at screening for the two treatment groups; circles (conventional follitropin alfa) and
squares (individualized follitropin delta) illustrate the observed proportion 1 SE; the lines are based on a logistic regression model with
treatment, AMH and log(AMH)2, and corresponding interactions in the linear predictor; the likelihood ratio test of treatment difference
indicates evidence of a treatment difference (P¼.037). (C) Proportion of women requiring OHSS preventive interventions and/or experiencing
OHSS by AMH levels for the two treatment groups; circles (conventional follitropin alfa) and squares (individualized follitropin delta) illustrate
the observed proportion 1 SE; the lines are based on a logistic regression model with treatment and log(AMH) and an interaction term in the
linear predictor; the likelihood ratio test of treatment difference indicates evidence of a treatment difference (P¼.037).
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Fertility and Sterility®and body weight, and conventional dosing of follitropin alfa,
individualized follitropin delta was noninferior to conventional
follitropin alfa for the primary efﬁcacy endpoints of ongoing
pregnancy and ongoing implantation rates in women undergo-
ing ovarian stimulation for IVF. Without any dose adjustments
during stimulation, individualized follitropin delta dosing re-
sulted in more women within the prespeciﬁed targeted ovarian
response of 8–14 retrieved oocytes, with fewer clinically relevant
cases of both poor and excessive ovarian responses, and a
reduced need for OHSS preventive measures.
Ovarian hyperstimulation syndrome remains the most
critical safety concern associated with the use of gonado-VOL. 107 NO. 2 / FEBRUARY 2017tropin preparations (17–19). In clinical practice, clinicians
need to act on increased risk of OHSS or symptoms of
hyperstimulation. Therefore, the trial design included a
composite endpoint of early OHSS and/or preventive
interventions for early OHSS (according to protocol-deﬁned
criteria), because recordings of only OHSS cases might lead
to an underestimation of hyperstimulation caused by
gonadotropins.
Large-scale population data have observed a positive
linear relationship between oocyte yield and live birth rates
up to 15 oocytes using conventional ovarian stimulation
(1, 2). Beyond 15 oocytes there is no increase in live birth393
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONrates, but the risk of OHSS increases exponentially (1),
prompting international guidance for implementation of
less aggressive stimulation while maintaining an adequate
oocyte yield (14). Although a target of 8–14 oocytes may be
potentially perceived as low, setting a higher oocyte target
would have been accompanied by an increased risk of
OHSS, because 1 standard deviation above the observed
mean oocyte yield was >15 oocytes in both treatment arms.
Furthermore, an oocyte yield of 15 or more was associated
with an increase in abdominal discomfort as determined by
visual analogue scale assessments made by the patients.
Because live birth rates from fresh blastocyst transfer cycles
were similar for those with the highest oocyte yield and
equivalent numbers of good-quality blastocysts were avail-
able for cryopreservation for both treatment arms, any
numeric difference in oocyte yield is unlikely to be advanta-
geous and only incurs risk. In that respect, the strict cycle
criteria for implementing OHSS preventive interventions
combined with the efﬁcacy of these preventive interventions
may have attenuated treatment differences in the incidence as
well as the severity of OHSS.
Consistent and predictable attainment of an optimized
ovarian response has previously not been feasible. The pre-
sent trial demonstrates that pretreatment characteristics can
predict the overall ovarian response proﬁle for a population
and be used to accurately estimate the frequency of a given
target response. Inevitably the proportion of women capable
of achieving a target of 8–14 oocytes will be primarily deter-
mined by the actual population undergoing ovarian stimula-
tion. In the present study, which used wide inclusion criteria,
it was predicted at trial enrolment that 42% of the individ-
ualized dosing group would yield an average of 8–14 oo-
cytes, and this prediction was validated, with 43%
attaining the predicted target yield (11). Future trials could
examine alternative patient groups and predicted response
proﬁles.
In the individualized dosing approach, the daily dose
was ﬁxed for the duration of stimulation while requests
for a dose change were implemented for follitropin alfa after
the ﬁrst 5 days of stimulation. Although some may consider
an initial starting dose of 150 IU/d of follitropin alfa inade-
quate, particularly for older women, it is consistent with
prescribing guidance, and we observed adverse events
even at this dose level. The differential effects on excessive
response or OHSS risk management may have been even
greater if the conventional follitropin alfa initial dose was
higher than 150 IU. That approximately one-third of the
women in both treatment groups had a request by the
fertility specialist for their dose to be altered, and predomi-
nantly that it be increased, may reﬂect the common belief
that higher doses of FSH are beneﬁcial. However, a meta-
analysis of 10 trials (n ¼ 1,952 IVF cycles) found no beneﬁt
of FSH doses above 200 IU/d (20), and analysis of 658,519
IVF cycles demonstrated a reduced live birth rate with FSH
doses above 300 IU/d independent of the age of the woman,
the number of oocytes retrieved, or underlying diagnosis
(21). The present trial showed that a ﬁxed dose regimen of
follitropin delta, without any implementation of requested
dose adjustments (the majority of which were requests for394dose increases), resulted in more women reaching the tar-
geted response. The ﬁxed dosing regimen of follitropin delta
might prove beneﬁcial to patients, in terms of simpler
dosing instructions as well as potential reduced monitoring
needs.
Previous trials (n ¼ 200–262) assessing individualiza-
tion of FSH doses by incorporating routinely available pre-
treatment characteristics, but not AMH, were statistically
inferior for their primary outcome of oocyte yield (22) or
have not been adopted clinically owing to concerns
regarding reproducibility, especially of the ultrasound mea-
surements (23). In randomized, controlled trials, AMH ex-
hibits superior prediction of ovarian response compared
with age, FSH, and AFC, with their inclusion in multivariate
prediction models not improving performance (8). Serum
concentrations of exogenous FSH are inversely associated
with body weight, and the clinical impact is particularly
evident when low gonadotropin doses are applied (10, 11,
24, 25). The present trial substantially extends both these
initial observations, by combining a human cell line
follitropin delta with a robust automated AMH assay and
body weight to individualize the FSH dose. It may also be
possible to develop and validate biomarker-driven dosing
strategies for other gonadotropins, utilizing a similar
modeling approach that was used for development of the
individualized follitropin delta algorithm.
Although this study has substantial strengths, including
its design, size, broad eligibility criteria, generalizability, and
the introduction of the biomarker AMH to guide dosing, we
acknowledge some limitations. The present study used AMH
analysis at a central laboratory, but the intra- and interassay
coefﬁcients of variation of the automated AMH assay have
been reported to be low across multiple platforms and sites
(26). Cumulative live-birth rates accounting for the transfer
of all fresh and frozen embryos are not available, because
some women proceeded directly to a further fresh cycle.
For both cumulative live birth and infant number, we do
not anticipate treatment differences, because both treatment
groups had an equivalent number of blastocysts available
for vitriﬁcation (20). A quality-of-life evaluation was not
undertaken, and whether fewer complications observed for
follitropin delta would be associated with a reduction in
treatment discontinuation is uncertain. Women diagnosed
with anovulatory polycystic ovarian syndrome were not
included. Nevertheless, in this trial the biggest difference
in safety was observed in women with high AMH, many
of whom would have polycystic ovaries (27), but all were
ovulatory. Because women with polycystic ovarian syn-
drome are at greatest risk of OHSS, the treatment differences
in safety may be expected to be larger, but this requires
conﬁrmation.CONCLUSION
Pretreatment risk stratiﬁcation and biomarker-driven treat-
ment modiﬁcation have been proposed as a means of
improving patient outcomes (28, 29). The present trial
demonstrates that an individualized follitropin delta
dosing is noninferior to conventional follitropin alfa withVOL. 107 NO. 2 / FEBRUARY 2017
Fertility and Sterility®respect to ongoing pregnancy rate, ongoing implantation
rate, and also live births, with a concomitant reduction
in iatrogenic complications, including preventive
interventions of OHSS.ESTHER-1 STUDY GROUP
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SUPPLEMENTAL TABLE 1
Inclusion/exclusion criteria.
Inclusion criteria
1. Informed consent documents signed before screening evaluations.
2. In good physical and mental health.
3. Premenopausal women between the ages of 18 and 40 y. The subjects must be at least 18 y (including the 18th birthday) when they sign the
informed consent and no more than 40 y (up to the day before the 41st birthday) at the time of randomization.
4. Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor
infertility, eligible for IVF and/or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm frommale partner or sperm
donor.
5. Infertility for at least 1 y before randomization for subjects aged%37 y or for at least 6 mo for subjects agedR38 y (not applicable in case of
tubal or severe male factor infertility).
6. The trial cycle will be the subject's ﬁrst controlled ovarian stimulation cycle for IVF/ICSI.
7. Regular menstrual cycles of 24–35 d (both inclusive), presumed to be ovulatory.
8. Hysterosalpingography, hysteroscopy, saline infusion sonography, or transvaginal ultrasound documenting a uterus consistent with
expected normal function (e.g., no evidence of clinically interfering uterine ﬁbroids deﬁned as submucous or intramural ﬁbroids larger
than 3 cm in diameter, no polyps, and no congenital structural abnormalities that are associated with a reduced chance of pregnancy)
within 1 y before randomization.
9. Transvaginal ultrasound documenting presence and adequate visualization of both ovaries, without evidence of signiﬁcant abnormality (e.g.,
no endometrioma greater than 3 cm or enlarged ovaries that would contraindicate the use of gonadotropins) and normal adnexa (e.g.,
no hydrosalpinx) within 1 y before randomization. Both ovaries must be accessible for oocyte retrieval.
10. Early follicular phase (cycle day 2–4) serum levels of FSH between 1 and 15 IU/L (results obtained within 3 mo before randomization).
11. Negative serum hepatitis B surface antigen, hepatitis C virus, and human immunodeﬁciency virus antibody tests within 2 y before
randomization.
12. Body mass index between 17.5 and 32.0 kg/m2 (both inclusive) at screening.
13. If aged%37 ywilling to accept single blastocyst transfer. If agedR38 ywilling to accept transfer of a single good-quality blastocyst or double
blastocyst transfer if no good-quality blastocyst is available.
14. Willing to accept transfer of maximum two blastocysts in cryopreserved cycles with blastocysts originating from the trial cycle and conducted
within 1 y after randomization.
Exclusion criteria
1. Known endometriosis stage III–IV.
2. One or more folliclesR10 mm observed on the transvaginal ultrasound before randomization on stimulation day 1.
3. Known history of recurrent miscarriage (deﬁned as three consecutive losses after ultrasound conﬁrmation of pregnancy (excluding ectopic
pregnancy) and before week 24 of pregnancy).
4. Known abnormal karyotype of subject or of her partner/sperm donor, as applicable, depending on source of sperm used for insemination in
this trial. In case partner sperm will be used and the sperm production is severely impaired (concentration
<1  106/mL), normal karyotype, including no Y-chromosome microdeletion, must be documented.
5. Any known clinically signiﬁcant systemic disease (e.g., insulin-dependent diabetes).
6. Known inherited or acquired thrombophilia disease.
7. Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
8. Known porphyria.
9. Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) that can compromise participation in the trial
with the exception of controlled thyroid function disease.
10. Known presence of anti-FSH antibodies (based on the information available in the subject's medical records; i.e., not based on the anti-FSH
antibody analyses conducted in the trial).
11. Known tumors of the ovary, breast, uterus, adrenal gland, pituitary, or hypothalamus that would contraindicate the use of gonadotropins.
12. Known moderate or severe impairment of renal or hepatic function.
13. Currently breast-feeding.
14. Undiagnosed vaginal bleeding.
15. Known abnormal cervical cytology of clinical signiﬁcance observed within 3 y before randomization (unless the clinical signiﬁcance has been
resolved).
16. Findings at the gynecologic examination at screening that preclude gonadotropin stimulation or are associated with a reduced chance of
pregnancy (e.g., congenital uterine abnormalities or retained intrauterine device).
17. Pregnancy (negative urinary pregnancy tests must be documented at screening and before randomization) or contraindication to pregnancy.
18. Known current active pelvic inﬂammatory disease.
19. Use of fertility modiﬁers during the last menstrual cycle before randomization, including DHEA or cycle programming with oral
contraceptives, progestogen, or estrogen preparations.
20. Use of hormonal preparations (except for thyroid medication) during the last menstrual cycle before randomization.
21. Known history of chemotherapy (except for gestational conditions) or radiotherapy.
22. Current or past (1 y before randomization) abuse of alcohol or drugs, and/or current (last month) intake of more than 14 units of alcohol per
week.
23. Current or past (3 mo before randomization) smoking habit of more than 10 cigarettes per day.
24. Hypersensitivity to any active ingredient or excipients in the medicinal products used in the trial.
25. Previous participation in the trial.
26. Use of any nonregistered investigational drugs during the last 3 mo before randomization.
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SUPPLEMENTAL TABLE 2
Individualized follitropin delta dosing regimen.
Serum AMH concentration
(pmol/L)
Daily dosea
(ﬁxed throughout
stimulation)
<15 12 mg
15–16 0.19 mg/kg
17 0.18 mg/kg
18 0.17 mg/kg
19–20 0.16 mg/kg
21–22 0.15 mg/kg
23–24 0.14 mg/kg
25–27 0.13 mg/kg
28–32 0.12 mg/kg
33–39 0.11 mg/kg
R40 0.10 mg/kg
a Maximum daily dose is 12 mg.
Nyboe Andersen. Individualized ovarian stimulation. Fertil Steril 2016.
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SUPPLEMENTAL TABLE 3
Risk proﬁle of patients with preventive interventions for early OHSS.
Parameter
No OHSS
or preventive
interventions
(n[ 1,236)
Late OHSS
(n[ 18)
Early OHSS
and no preventive
interventions
(n[ 27)
Preventive
interventions
and no early
OHSS (n[ 35)
Preventive
interventions
and early
OHSS (n[ 10)
Oocytes retrieved 9.2 (5.6) 14.4 (6.8)a 15.7 (6.0)a 20.5 (7.1)a 26.9 (10.4)a
E2 (pmol/L) 5,856 (3,381) 7,450 (3,943)
b 11,530 (6,632)a 10,552 (6,656)a 16,392 (9,274)a
Inhibin B (pg/mL) 849 (545) 1,346 (664)a 1,773 (822)a 2,120 (659)a 2,794 (1,021)a
Inhibin A (pg/mL) 347 (184) 442 (201)b 663 (404)a 653 (271)a 998 (411)a
Note: Data are mean (SD); both treatment groups combined. Groups are compared pairwise using Wilcoxon's test.
a P< .001 vs. the ‘‘no OHSS or preventive interventions’’ population.
b P< .05 vs. the ‘‘no OHSS or preventive interventions’’ population.
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SUPPLEMENTAL FIGURE 1
1501 women assessed for eligibility
172 excluded
103 not meeting eligibility criteria
41 withdrew their consent
28 other reasons 
1329 randomized
666 allocated to individualized follitropin delta dosing 663 allocated to conventional follitropin alfa dosing
636 had triggering of final follicular maturation 643 had triggering of final follicular maturation
1 discontinued due to adverse event
29 had cycle cancellation
25 due to poor response
4 due to other reason
18 had cycle cancellation
due to poor response
635 had oocyte retrieval procedure 643 had oocyte retrieval procedure
1 had no oocytes retrieved
13 had cycle management with
no transfer
46 had no blastocysts for
transfer
13 discontinued
7 had adverse event
6 due to other reason 
3 had no oocytes retrieved
27 had cycle management with
no transfer
40 had no blastocysts for
transfer
13 discontinued
10 had adverse event
3 due to other reason 
562 had assessment of hCG 560 had assessment of hCG
305 had negative hCG
7 had menses
250 had clinical pregnancy assessment 259 had clinical pregnancy assessment
294 had negative hCG
7 had menses
39 had no vital pregnancy
2 had miscarriage
38 had no vital pregnancy
209 had ongoing pregnancy assessment 221 had ongoing pregnancy assessment
204 had confirmed ongoing pregnancy 209 had confirmed ongoing pregnancy
5 had miscarriage 12 had miscarriage    
198 had live birth
201 live-born neonates
195 singletons
6 twins
203 had live birth
208 live-born neonates
196 singletons
12 twins
6 had miscarriage 6 had miscarriage    
198 had live neonates 4 weeks after birth
195 singletons
6 twins
201 had live neonates 4 weeks after birth
196 singletons
9 twins
2 had losses   
560 had blastocyst transfer
536 had single transfer
24 had double transfer
562 had blastocyst transfer
539 had single transfer
23 had double transfer
665 received allocated intervention
1 was not exposed to study drug
661 received allocated intervention
2 were not exposed to study drug
665 analyzed in the modified intention-to-treat (mITT)
analysis set (randomized and exposed)
623 analyzed per protocol
661 analyzed in the modified intention-to-treat (mITT)
analysis set (randomized and exposed)
632 analyzed per protocol
Trial and participant ﬂow.
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